Outlook Therapeutics, Inc.
Outlook Therapeutics, Inc. (OTLK): 2 pipeline candidates · 2 upcoming catalysts · ~5 mo cash runway · 1 clinical trial. Updated within the last hour.
BioSniper Score
6-factor signal · derived from public data
4.5 months
D/E -1.75 · 0% dilution
Lead: BLA Filed
2 candidates
2 upcoming, next in ~531d
6 buys · 0 sells (180d)
A transparent, data-derived signal for Outlook Therapeutics, Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$140.2M
Cash
$7.7M
Quarterly Burn
$7.8M
Runway
4.5 mo
Revenue
—
Cash Runway vs Catalysts
A catalyst falls after projected cash runway — potential financing / dilution risk before it hits.
Pipeline (2 candidates)
| Drug | Phase |
|---|---|
| ons-5010 | Phase 3 |
| ons-5010/lytenava | BLA Filed |
Upcoming Catalysts (2)
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
55
Total value held
$2.6M
| Holder | Shares | Value |
|---|---|---|
| armistice capital, llc | 4,168,000 | $858K |
| vanguard capital management llc | 3,934,320 | $810K |
| geode capital management, llc | 603,606 | $124K |
| gilpin wealth management, llc | 600,162 | $124K |
| blackrock, inc. | 477,471 | $98K |
| commonwealth equity services, llc | 470,000 | $97K |
| renaissance technologies llc | 255,157 | $53K |
| nine masts capital ltd | 232,546 | $48K |
| connective capital management, llc | 200,000 | $41K |
| citadel advisors llc | 194,500 | $40K |
Showing top 10 of 55 institutional holders of Outlook Therapeutics, Inc.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in Outlook Therapeutics, Inc.'s pipeline?
Outlook Therapeutics, Inc. (OTLK) has 2 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Outlook Therapeutics, Inc.'s lead drug candidate?
Outlook Therapeutics, Inc.'s most advanced tracked candidate is ons-5010 (Phase 3) for FDA acknowledged receipt of BLA resubmission, determined it is a Class 1 review with a PDUFA goal date of December 31, 2025..
What is Outlook Therapeutics, Inc.'s next catalyst?
Outlook Therapeutics, Inc.'s next tracked catalyst is a Phase3_Topline event — "Phase 3 Topline: A 3-month Study to Compare the Safety of ONS-5010 in Vials Versus PFS in Subjects With Visual Impair" — expected December 1, 2027.
What is Outlook Therapeutics, Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Outlook Therapeutics, Inc. has approximately 4.5 months of cash runway.
What is Outlook Therapeutics, Inc.'s market capitalization?
Outlook Therapeutics, Inc.'s market capitalization is approximately $140.2M.
Get the full picture on Outlook Therapeutics, Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.